Comparison of Tacrolimus Intra-Patient Variability during 6–12 Months after Kidney Transplantation between CYP3A5 Expressers and Nonexpressers

A high intra-patient variability (IPV) of tacrolimus exposure is associated with poor long-term kidney transplantation outcomes. To assess the influence of cytochrome P450 (CYP) 3A5 genetic polymorphisms on tacrolimus IPV, 188 clinically stable kidney transplant recipients, who had received an immediate-release tacrolimus-based immunosuppressive regimen, were enrolled in this retrospective cohort study. Genotyping of CYP3A5*3 (rs776746) was performed and 110 (58.5%) were identified as CYP3A5 expressers and 78 (41.5%) as nonexpressers. Whole blood tacrolimus concentrations were analyzed by chemiluminescent microparticle immunoassay. Dose-adjusted trough tacrolimus concentrations (C0/D) measured at months 6, 9, and 12 were used to determine IPV. There were no significant differences in the IPV estimated by the coefficient of variation, the IPV calculated by mean absolute deviation method, and the proportions of recipients with the IPV estimated by the coefficient of variation of 30% or more between CYP3A5 expressers and nonexpressers (p = 0.613, 0.686, and 0.954, respectively). Tacrolimus C0/D in CYP3A5 expressers was approximately half of those in nonexpressers, overall (p < 0.001). In both CYP3A5 expressers and nonexpressers, tacrolimus C0/D increased gradually from month 6 to month 12 (p = 0.021). There was no evidence that the CYP3A5 polymorphisms significantly influence tacrolimus IPV during the 6 to 12 months after kidney transplantation.

[1]  P. V. D. van der Boog,et al.  Model-informed precision dosing to optimise immunosuppressive therapy in renal transplantation. , 2021, Drug discovery today.

[2]  A. Israni,et al.  OPTN/SRTR 2019 Annual Data Report: Kidney , 2021, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[3]  N. Larpparisuth,et al.  High Intrapatient Variability in Tacrolimus Exposure Calculated Over a Long Period Is Associated With De Novo Donor-Specific Antibody Development and/or Late Rejection in Thai Kidney Transplant Patients Receiving Concomitant CYP3A4/5 Inhibitors , 2020, Therapeutic drug monitoring.

[4]  C. Dandara,et al.  CYP3A5 polymorphisms and their effects on tacrolimus exposure in an ethnically diverse South African renal transplant population. , 2020, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[5]  D. Kuypers.  Intrapatient Variability of Tacrolimus Exposure in Solid Organ Transplantation: A Novel Marker for Clinical Outcome , 2020, Clinical pharmacology and therapeutics.

[6]  J. V. van Hooff,et al.  Impact of CYP3A5 Genetic Polymorphism on Intrapatient Variability of Tacrolimus Exposure in Chinese Kidney Transplant Recipients. , 2019, Transplantation proceedings.

[7]  U. Christians,et al.  Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report , 2019, Therapeutic drug monitoring.

[8]  C. Süsal,et al.  Late intra‐patient tacrolimus trough level variability as a major problem in kidney transplantation: A Collaborative Transplant Study Report , 2019, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[9]  W. Guan,et al.  Tacrolimus trough and dose intra‐patient variability and CYP3A5 genotype: Effects on acute rejection and graft failure in European American and African American kidney transplant recipients , 2018, Clinical transplantation.

[10]  C. Sukasem,et al.  Impact of POR and CYP3A5 Polymorphisms on Trough Concentration to Dose Ratio of Tacrolimus in the Early Post-operative Period Following Kidney Transplantation , 2018, Therapeutic drug monitoring.

[11]  G. Prasad,et al.  CYP3A5 polymorphisms in renal transplant recipients: influence on tacrolimus treatment , 2018, Pharmacogenomics and personalized medicine.

[12]  T. Srinivas,et al.  Tacrolimus Trough Concentration Variability and Disparities in African American Kidney Transplantation , 2017, Transplantation.

[13]  M. Willicombe,et al.  High Intrapatient Variability of Tacrolimus Levels and Outpatient Clinic Nonattendance Are Associated With Inferior Outcomes in Renal Transplant Patients , 2017, Transplantation direct.

[14]  A. Jardine,et al.  High Intrapatient Tacrolimus Variability Is Associated With Worse Outcomes in Renal Transplantation Using a Low-Dose Tacrolimus Immunosuppressive Regime , 2017, Transplantation.

[15]  W. Weimar,et al.  A high intrapatient variability in tacrolimus exposure is associated with poor long‐term outcome of kidney transplantation , 2016, Transplant international : official journal of the European Society for Organ Transplantation.

[16]  S. Brouard,et al.  Failure of Calcineurin Inhibitor (Tacrolimus) Weaning Randomized Trial in Long‐Term Stable Kidney Transplant Recipients , 2016, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[17]  M. Arias,et al.  Within-Patient Variability in Tacrolimus Blood Levels Predicts Kidney Graft Loss and Donor-Specific Antibody Development , 2016, Transplantation.

[18]  T. Vermeulen,et al.  High Intrapatient Variability of Tacrolimus Concentrations Predicts Accelerated Progression of Chronic Histologic Lesions in Renal Recipients , 2016, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[19]  S. Vadcharavivad,et al.  Population pharmacokinetics of tacrolimus in Thai kidney transplant patients: comparison with similar data from other populations , 2016, Journal of clinical pharmacy and therapeutics.

[20]  W. Guan,et al.  Genomewide Association Study of Tacrolimus Concentrations in African American Kidney Transplant Recipients Identifies Multiple CYP3A5 Alleles , 2016, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[21]  C. O’Seaghdha,et al.  Tacrolimus trough-level variability predicts long-term allograft survival following kidney transplantation , 2016, Journal of Nephrology.

[22]  K. Verbeke,et al.  Progressive decline in tacrolimus clearance after renal transplantation is partially explained by decreasing CYP3A4 activity and increasing haematocrit. , 2015, British journal of clinical pharmacology.

[23]  P. Nickerson,et al.  Adverse Outcomes of Tacrolimus Withdrawal in Immune-Quiescent Kidney Transplant Recipients. , 2015, Journal of the American Society of Nephrology : JASN.

[24]  D. Hesselink,et al.  Intra-patient variability in tacrolimus exposure: causes, consequences for clinical management. , 2015, Transplantation reviews.

[25]  S. Kim,et al.  Time-dependent variability in tacrolimus trough blood levels is a risk factor for late kidney transplant failure. , 2014, Kidney international.

[26]  D. Hesselink,et al.  The Role of Pharmacogenetics in the Disposition of and Response to Tacrolimus in Solid Organ Transplantation , 2014, Clinical Pharmacokinetics.

[27]  V. Haufroid,et al.  Impact of CYP3A4*22 Allele on Tacrolimus Pharmacokinetics in Early Period After Renal Transplantation: Toward Updated Genotype-Based Dosage Guidelines , 2013, Therapeutic drug monitoring.

[28]  D. Holt,et al.  CYP3A5 Genotype Had no Impact on Intrapatient Variability of Tacrolimus Clearance in Renal Transplant Recipients , 2013, Therapeutic drug monitoring.

[29]  K. Moon,et al.  Impact of Tacrolimus Intraindividual Variability and CYP3A5 Genetic Polymorphism on Acute Rejection in Kidney Transplantation , 2012, Therapeutic drug monitoring.

[30]  Lawrence X. Yu,et al.  Implementation of a Reference-Scaled Average Bioequivalence Approach for Highly Variable Generic Drug Products by the US Food and Drug Administration , 2012, The AAPS Journal.

[31]  P. Canonico,et al.  The effect of CYP3A5 6986A>G and ABCB1 3435C>T on tacrolimus dose-adjusted trough levels and acute rejection rates in renal transplant patients: a systematic review and meta-analysis. , 2012, Pharmacogenetics and genomics.

[32]  D. Gjertson,et al.  Monitoring Nonadherence and Acute Rejection With Variation in Blood Immunosuppressant Levels in Pediatric Renal Transplantation , 2011, Transplantation.

[33]  W. Weimar,et al.  CYP3A5 Genotype Is Not Related to the Intrapatient Variability of Tacrolimus Clearance , 2011, Therapeutic drug monitoring.

[34]  A. Israni,et al.  Novel Polymorphisms Associated With Tacrolimus Trough Concentrations: Results From a Multicenter Kidney Transplant Consortium , 2011, Transplantation.

[35]  W. Weimar,et al.  High within-patient variability in the clearance of tacrolimus is a risk factor for poor long-term outcome after kidney transplantation. , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[36]  C. Staatz,et al.  Effect of CYP3A and ABCB1 Single Nucleotide Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Calcineurin Inhibitors: Part I , 2010, Clinical pharmacokinetics.

[37]  P. Halloran,et al.  Reduced exposure to calcineurin inhibitors in renal transplantation. , 2007, The New England journal of medicine.

[38]  Edgar Erdfelder,et al.  G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences , 2007, Behavior research methods.

[39]  C. Staatz,et al.  Clinical Pharmacokinetics and Pharmacodynamics of Tacrolimus in Solid Organ Transplantation , 2004, Clinical pharmacokinetics.

[40]  R. Kim,et al.  Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women. , 2003, Pharmacogenetics.